---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-005933"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:53:48.100906+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aileron receives Nasdaq deficiency notice for missing annual meeting; appoints Marcum as auditor

## Summary
- Received Nasdaq notice on Jan 4, 2024 for failing to hold annual meeting within 12 months after FY2022 end.
- Must submit compliance plan by Feb 20, 2024; Nasdaq may grant extension to June 28, 2024.
- Appointed Marcum LLP as independent auditor for FY2023, effective Jan 9, 2024.
- No prior consultations with Marcum or disagreements with prior auditor reported.

## SEC filing metadata
- accession: 0001193125-24-005933
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 4.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524005933/0001193125-24-005933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524005933/d78429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-005933
- JSON: https://secwatch.observer/filing/0001193125-24-005933.json
- Plain text: https://secwatch.observer/filing/0001193125-24-005933.txt

## Key facts
- Auditor Changes
  Rein Therapeutics, Inc. engaged Marcum LLP as its auditor.
  - Action: engagement
  - Auditor: Marcum LLP
  source text: On January 10, 2024, the Audit Committee of the Board of Directors of the Company appointed Marcum LLP ("Marcum") as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023. The Company formally engaged Marcum on January 9, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524005933/0001193125-24-005933-index.htm
- Listing & Compliance Notices
  Rein Therapeutics, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Rules: 5620(a)
  source text: January 4, 2024, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to hold its annual meeting of shareholders within twelve (12) months after its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a) (the “Annual Meeting Listing Rule”). The Notice does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. The Notice states that the Company has 45 calendar
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312524005933/0001193125-24-005933-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.